Added Revolutions Medical President Tom O'Brien, "And likely as important to cost-sensitive agencies and hospitals, we will bring the Rev Vac to market at less than half the published cost of the VanishPoint safety needle. Cost is a function of design, parts count and manufacturing investment; the financial commitment we have made to engineering a patented design of such elegant simplicity allows us to outperform competitive products, while keeping production costs lower than our peers.

"This announcement confirms the magnitude of the opportunity before us, and we believe our product's competitive advantages will well position Revolutions Medical to pursue and win business of this kind."

Revolutions Medical is currently finalizing Rev Vac safety syringe production schedules, gearing up global distribution, and having discussions with potential corporate partners worldwide.

SOURCE: Revolutions Medical Corp.